alexa
Reach Us +1-217-403-9671
A QUICK ASSAY OF PATHOGENIC BACTERIA IN KIDNEY INFECTION USING GOLD NANO-BIOSENSORS | 8329
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A QUICK ASSAY OF PATHOGENIC BACTERIA IN KIDNEY INFECTION USING GOLD NANO-BIOSENSORS

International Conference & Exhibition Bioequivalence and Bioavailability

Subhash C. Basu, Sara Seggerson, Kunal Saxena, Rocio del A. Cordona, Clare Lefave , Manju Basu, Juan Jiang , Albert Miller

ScientificTracks Abstracts: J Bioequiv Availab 2010

DOI: 10.4172/0975-0851.1000001

Abstract
A large number of cytotoxic/genotoxic and targeted oncology drugs are currently in clinical drug development. In addition to the general challenges faced in drug development, one of the key challenge in developing a new oncology drug is assessing BA/BE during clinical development, as many of the newer oncology agents are for oral use. The BA/BE assessment challenge comes form genotoxicity of these agents, which means the assessment can be conducted only in cancer patients. As a result, BA/BE assessments are integrated in clinical trials in cancer patients. The presentation will cover ethical considerations for incorporating BA/BE assessments in clinical trials in cancer patients along with clinical operation issues that govern successful conduct of such evaluations. The presentation will also cover types of formulation development issues that are encountered during clinical development of oncologic agents along with combination of in vitro, pre-clinical and clinical BA/BE strategies that are applied to support the clinical development programs. Finally, importance of early understanding of the cause of pharmacokinetic variability and mitigating the issues of limited statistical power in assessing BA/BE for oncologic agents will be discussed
Biography
Top